In Vitro Assessment of the Allelic Variants of Cytochrome P450

Ingelman-Sundberg, 2007, Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects, Pharmacol. Ther., 116, 496, 10.1016/j.pharmthera.2007.09.004 Johansson, 2011, Genetic polymorphism and toxicology—with emphasis on cytochrome p450, Toxicol. Sci., 120, 1, 10.1093/toxsci/kfq374 Evans, 1999, Pharmacogenomics: translating functional genomics into rational therapeutics, Science, 286, 487491, 10.1126/science.286.5439.487 Goldstein, 2003, Pharmacogenetics goes genomic, Nat. Rev. Genet., 4, 937, 10.1038/nrg1229 Bertz, 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions, Clin. Pharmacokinet., 32, 210, 10.2165/00003088-199732030-00004 Chen, 1993, Structure-function studies of human aromatase, J. Steroid Biochem. Mol. Biol., 44, 347, 10.1016/0960-0760(93)90238-R Gomez, 2010, Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity, Mol. Pharmacol., 78, 1004, 10.1124/mol.110.067652 Sethumadhavan, 1991, Estrogen synthetase (aromatase). The cytochrome P-450 component of the human placental enzyme is a glycoprotein, Mol. Cell. Endocrinol., 78, 25, 10.1016/0303-7207(91)90182-R Shimozawa, 1993, Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen, J. Biol. Chem., 268, 21399, 10.1016/S0021-9258(19)36937-6 Koch, 1991, P450 phosphorylation in isolated hepatocytes and in vivo, Methods Enzymol., 206, 305, 10.1016/0076-6879(91)06100-H Menez, 1993, Phosphorylation of cytochrome P4502E1 (CYP2E1) by calmodulin dependent protein kinase, protein kinase C and cAMP dependent protein kinase, Alcohol Alcohol., 28, 445451 Barnes, 1991, Expression and enzymatic activity of recombinant cytochrome P450 17 alphahydroxylase in Escherichia coli, Proc. Natl. Acad. Sci. USA, 88, 5597, 10.1073/pnas.88.13.5597 Gillam, 1994, Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties, Arch. Biochem. Biophys., 312, 59, 10.1006/abbi.1994.1280 Gillam, 1995, Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization, Arch. Biochem. Biophys., 319, 540, 10.1006/abbi.1995.1329 Gillam, 1995, Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5$ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities, Arch. Biochem. Biophys., 317, 374, 10.1006/abbi.1995.1177 Guo, 1994, Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5' substitution, stabilization, purification, spectral characterization, and catalytic properties, Arch. Biochem. Biophys., 312, 436, 10.1006/abbi.1994.1330 Richardson, 1995, A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli, Arch. Biochem. Biophys., 323, 87, 10.1006/abbi.1995.0013 Sandhu, 1993, Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity, Arch. Biochem. Biophys., 306, 443, 10.1006/abbi.1993.1536 Sandhu, 1994, Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme, Arch. Biochem. Biophys., 309, 168, 10.1006/abbi.1994.1099 Oeda, 1985, Expression of rat liver cytochrome P-450MC cDNA in Saccharomyces cerevisiae, DNA, 4, 203, 10.1089/dna.1985.4.203 Murakami, 1986, Expression of rat NADPH-cytochrome P-450 reductase cDNA in Saccharomyces cerevisiae, DNA, 5, 1, 10.1089/dna.1986.5.1 Uno, 1989, Identification of regions functioning in substrate interaction of rabbit liver cytochrome P-450 (laurate (omega-1)-hydroxylase), J. Biochem., 106, 569, 10.1093/oxfordjournals.jbchem.a122897 Iwasaki, 1994, Inherent versatility of P-450 oxygenase. Conferring dehydroepiandrosterone hydroxylase activity to P-450 2a-4 by a single amino acid mutation at position 117, J. Biol. Chem., 269, 9079, 10.1016/S0021-9258(17)37079-5 Asseffa, 1989, Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus, Arch. Biochem. Biophys., 274, 481, 10.1016/0003-9861(89)90461-X Gonzalez, 1991, Expression of mammalian cytochrome P450 using baculovirus, Methods Enzymol., 206, 93, 10.1016/0076-6879(91)06080-M Higashi, 1991, Functional analysis of mutant P450(C21) genes in COS cell expression system, Methods Enzymol., 206, 166, 10.1016/0076-6879(91)06087-J Ingelman-Sundberg, 1999, Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment, Trends Pharmacol. Sci., 20, 342349, 10.1016/S0165-6147(99)01363-2 Kronbach, 1989, Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4, Proc. Natl. Acad. Sci. USA, 86, 8262, 10.1073/pnas.86.21.8262 Luo, 1994, Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16-hydroxylase to a 15 alpha-hydroxylase, Arch. Biochem. Biophys., 309, 52, 10.1006/abbi.1994.1083 Minowa, 1990, Functional expression of microsomal and mitochondrial cytochrome P-450 (d and SCC) in COS-7 cells from cloned cDNA, Cell Struct. Funct., 15, 21, 10.1247/csf.15.21 Kusano, 2001, Microsomal p450s use specific proline-rich sequences for efficient folding, but not for maintenance of the folded structure, J. Biochem., 129, 259, 10.1093/oxfordjournals.jbchem.a002853 Chida, 1999, A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype, Pharmacogenetics, 9, 287, 10.1097/00008571-199906000-00003 Nishida, 2000, CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10, Pharmacogenetics, 10, 567, 10.1097/00008571-200008000-00010 Koyama, 1994, Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alphahydroxylation and S-mephenytoin 4′-hydroxylation phenotypes, J. Pharmacol. Exp. Ther., 271, 860 Daly, 1996, idle, J. R., ingelman-Sundberg, M., ishizaki, T., Jacqz-Aigrain, E., Meyer, u. A., Nebert, D. W., Steen, V. M., Wolf, C. R. and Zanger, U. M.: Nomenclature for human CYP2D6 alleles, Pharmacogenetics, 6, 193, 10.1097/00008571-199606000-00001 Johansson, 1994, Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation, Mol. Pharmacol., 46, 452 Takahashi, 1998, Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes, Pharmacogenetics, 8, 365, 10.1097/00008571-199810000-00001 Takanashi, 2000, CYP2C9 ile359 and Leu359 variants: enzyme kinetic study with seven substrates, Pharmacogenetics, 10, 95, 10.1097/00008571-200003000-00001 Maekawa, 2009, Substratedependent functional alterations of seven CYP2C9 variants found in Japanese subjects, Drug Metab. Dispos., 37, 1895, 10.1124/dmd.109.027003 Kimura, 1998, Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population, Ther. Drug Monit., 20, 243, 10.1097/00007691-199806000-00001 Ieiri, 1996, Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects, Clin. Pharmacol. Ther., 59, 647653, 10.1016/S0009-9236(96)90004-1 Furuta, 1999, CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans, Clin. Pharmacol. Ther., 65, 552, 10.1016/S0009-9236(99)70075-5 Wang, 2011, Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4 -hydroxylation and omeprazole 5/-hydroxylation, Drug Metab. Dispos., 39, 830, 10.1124/dmd.110.037549 Hesse, 2000, CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants, Drug Metab. Dispos., 28, 1176 Hidestrand, 2001, CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes, Drug Metab. Dispos., 29, 1480 Roy, 1999, Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles, Drug Metab. Dispos., 27, 655 Salonen, 2003, Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems, Drug Metab. Dispos., 31, 1093, 10.1124/dmd.31.9.1093 Jinno, 2003, Functional characterization of cytochrome P450 2B6 allelic variants, Drug Metab. Dispos., 31, 398, 10.1124/dmd.31.4.398 Lang, 2004, Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles, J. Pharmacol. Exp. Ther., 311, 34, 10.1124/jpet.104.068973 Klein, 2005, Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz, Pharmacogenet. Genomics, 15, 861, 10.1097/01213011-200512000-00004 Rotger, 2007, Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7, Pharmacogenet. Genomics, 17, 885, 10.1097/FPC.0b013e3282ef5cd1 Watanabe, 2010, Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22), Pharmacogenet. Genomics, 20, 459, 10.1097/FPC.0b013e32833bba0e Honda, 2011, Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether, Drug Metab. Dispos., 39, 1860, 10.1124/dmd.111.040352 Wennerholm, 2001, Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity, Pharmacogenetics, 11, 417, 10.1097/00008571-200107000-00005 Zanger, 2001, Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6, Pharmacogenetics, 11, 573, 10.1097/00008571-200110000-00004 Ramamoorthy, 2002, Reduced (+/®)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro, Biochem. Pharmacol., 63, 2111, 10.1016/S0006-2952(02)01028-6 Bapiro, 2002, The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations, Biochem. Pharmacol., 64, 1387, 10.1016/S0006-2952(02)01351-5 Marcucci, 2002, Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine, Drug Metab. Dispos., 30, 595, 10.1124/dmd.30.5.595 Yu, 2002, Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms, J. Pharmacol. Exp. Ther., 303, 1291, 10.1124/jpet.102.039891 Sakuyama, 2008, Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57), Drug Metab. Dispos, 36, 2460, 10.1124/dmd.108.023242 Kagimoto, 1990, Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine, Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem., 265, 17209 Evert, 1997, Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells, Naunyn Schmiedebergs Arch. Pharmacol., 355, 309, 10.1007/PL00004948 Fukuda, 2000, The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6, Arch. Biochem. Biophys., 380, 303, 10.1006/abbi.2000.1936 Ramamoorthy, 2001, Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates, Pharmacogenetics, 11, 477, 10.1097/00008571-200108000-00003 Nakamura, 2002, CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability, Biochem. Biophys. Res. Commun., 293, 969, 10.1016/S0006-291X(02)00328-5 Hanioka, 2006, Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae, Biochem. Pharmacol., 71, 1386, 10.1016/j.bcp.2006.01.019 Shen, 2007, Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17, Drug Metab. Dispos., 35, 1292, 10.1124/dmd.107.015354 Matsunaga, 2009, Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese, Drug Metab. Dispos., 37, 699, 10.1124/dmd.108.026096 Bogni, 2005, Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles, Toxicol. In Vitro, 19, 621, 10.1016/j.tiv.2005.04.001 Yokoi, 1996, A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype, Pharmacogenetics, 6, 395, 10.1097/00008571-199610000-00003 Zhang, 2009, Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes, Drug Metab. Dispos., 37, 1, 10.1124/dmd.108.023663 Allorge, 2005, Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution, Proteins, 59, 339, 10.1002/prot.20399 Allorge, 2001, In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism, Pharmacogenetics, 11, 739, 10.1097/00008571-200111000-00014 Toscano, 2006, Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events, Pharmacogenet. Genomics, 16, 755, 10.1097/01.fpc.0000230112.96086.e0 Klein, 2007, A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6, Drug Metab. Dispos., 35, 1247, 10.1124/dmd.107.015149 Kaminsky, 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe, Mol. Pharmacol., 43, 234 Veronese, 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily, Biochem. J., 289, 533, 10.1042/bj2890533 Rettie, 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9, Pharmacogenetics, 4, 3942, 10.1097/00008571-199402000-00005 Sullivan-Klose, 1996, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics, 6, 341, 10.1097/00008571-199608000-00007 Chang, 1997, Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation, Pharmacogenetics, 7, 211, 10.1097/00008571-199706000-00006 Kumar, 1997, Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001), Drug Metab. Dispos., 25, 110 Yamazaki, 1998, Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes, Biochem. Pharmacol., 56, 243, 10.1016/S0006-2952(98)00133-6 Rettie, 1999, A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin, Epilepsy Res., 35, 253, 10.1016/S0920-1211(99)00017-0 Yasar, 2001, Role of CYP2C9 polymorphism in losartan oxidation, Drug Metab. Dispos., 29, 1051 Tang, 2001, In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics, Pharmacogenetics, 11, 223, 10.1097/00008571-200104000-00006 Sandberg, 2002, Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase, Br. J. Clin. Pharmacol., 54, 423, 10.1046/j.1365-2125.2002.01660.x Thijssen, 2003, Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype, Clin. Pharmacol. Ther., 74, 61, 10.1016/S0009-9236(03)00088-2 Lundblad, 2005, Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes, Biochem. Biophys. Res. Commun., 327, 1052, 10.1016/j.bbrc.2004.12.116 Bland, 2005, CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin, Biochem. Pharmacol., 70, 1096, 10.1016/j.bcp.2005.07.007 Hanatani, 2001, CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro, Pharmacogenomics J., 1, 288, 10.1038/sj.tpj.6500063 Dickmann, 2001, Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans, Mol. Pharmacol., 60, 382, 10.1124/mol.60.2.382 Tracy, 2002, Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles, Drug Metab. Dispos., 30, 385, 10.1124/dmd.30.4.385 Hanatani, 2003, No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3, Eur. J. Clin. Pharmacol., 59, 233, 10.1007/s00228-003-0603-5 Guo, 2005, Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13, Xenobiotica, 35, 853, 10.1080/00498250500256367 Guo, 2005, Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans, Drug Metab. Dispos., 33, 749, 10.1124/dmd.105.003616 Ieiri, 2000, Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis, Ther. Drug Monit., 22, 237, 10.1097/00007691-200006000-00001 Blaisdell, 2004, Discovery of new potentially defective alleles of human CYP2C9, Pharmacogenetics, 14, 527, 10.1097/01.fpc.0000114759.08559.51 DeLozier, 2005, Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians, J. Pharmacol. Exp. Ther., 315, 1085, 10.1124/jpet.105.091181 Herman, 2007, Characterization of the novel defective CYP2C9*24 allele, Drug Metab. Dispos., 35, 831, 10.1124/dmd.106.013722 Maekawa, 2006, Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese, Pharmacogenet. Genomics, 16, 497514, 10.1097/01.fpc.0000215069.14095.c6 Yin, 2008, Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan, Hypertens. Res., 31, 1549, 10.1291/hypres.31.1549 Lee, 2009, Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole, Drug Metab. Dispos., 37, 2262, 10.1124/dmd.109.028175 Ibeanu, 1998, An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians, Pharmacogenetics, 8, 129, 10.1097/00008571-199804000-00006 Ibeanu, 1998, Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin, J. Pharmacol. Exp. Ther., 286, 1490 Ibeanu, 1999, A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin, J. Pharmacol. Exp. Ther., 290, 635 Blaisdell, 2002, Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics, 12, 703, 10.1097/00008571-200212000-00004 Hanioka, 2007, Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population, Xenobiotica, 37, 342, 10.1080/00498250601127038 Hanioka, 2008, Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae, Basic Clin. Pharmacol. Toxicol., 102, 388, 10.1111/j.1742-7843.2008.00222.x Wang, 2006, Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz, Pharmacogenet. Genomics, 16, 191, 10.1097/01.fpc.0000189797.03845.90